Drug discovery

oculoplaniaballtownBiotechnology

Dec 1, 2012 (4 years and 9 months ago)

197 views


Drug Development KMG045
/

BIO523


Program
s
:

Biotechnology
and Bioinformatics
program
s

(
Chalmers
);

Molecular
Biolo
gy and Systems Biology programs

(
GU
).


Place in program
:

Year 4/5, optional


Number of students:

No limitation


Course leader
:

Per Sunnerhagen
, Department of Cell

and Molecular B
iology (CMB),
Göteborg University
;
Medicinaregatan 9C, 413 90 Göteborg / Box 462
405 30 Göteborg

Phone: 031/786 3830; mobile 0705/294180; fax: 031/786 3801

E
-
mail:
Per.S
unnerhagen@cmb.gu.se


Changes in the schedule and other messages regarding the course will
be distributed through E
-
mail an
d
/or posted at GUL (GU) or the
Student portal

(
Chalmers
)
. Handouts and literature will likewise be
available at these sites.


Length
:


7.5 ECTS


Prerequisites
:

Only compulsory courses in the first 3 years of the Biotechnology
program

(Chalmers)
,
the first 2 years of the Molecular Biology program

(GU)
,
or equivalent.


Time
:



Period 2, fall term 2010


Aim
:

The emphasis is put on the

first steps in development of a new
pharmaceutical, “drug discovery”. The premise is that this process
starts with identification of the biomolecule (“drug target”) that the
pharmaceutical is intended to affect. Examples are also given of
existing drugs,
how they have been developed, and their mechanisms of
action. The course is intended to give an overview of the area, and will
cover a wide spectrum of approaches. The course is mostly theoretical,
but in certain parts practical demonstrations may be inclu
ded.


Literature
:

Scientific review papers, see separate list.


Accessory reading: “
Genomics in Drug Discovery and Development
”,
D. Semizarov and E.

Blomme
, 2008. John Wiley,
ISBN: 978
-
0
-
470
-
09604
-
8


Exam
:

Written, at the end of the course. In addition, e
ssay subjects will be
presented to be worked on individually during the course. These are
submitted at the end of the course and will be graded. The grade for the
essays and the written exam are added to give the final score.


Items in course:

Lectures, p
ractical demonstrations, and individual projects.



Individual projects:

As part of the examination, individual projects in the form of essay
subjects are used. At one specific time in the course, the subjects
(usually three), which are of the essay type
, are presented. Each topic is
linked to one or more of the subjects in the course. Each student
chooses
one

of these topics to answer. The topics can be of
e.g.

the type
”given a certain problem within the do
main of the course, describe how

you would go a
bout to solve it”; or a literature study of a certain area.
The essays can be written with free consultation of the literature;
however each student must produce an individual essay, and the essays
should be produced independently of the teachers on the co
urse.




The essays, in Swedish or English, are reported in written form,
maximum 2000 words. They are submitted on paper or per E
-
mail at the
end of the course and will be graded of the person who formulated the
respective topic. The grades of the indivi
dual projects and the written
exam are added to produce the final score. The individual projects
contribute about 25 % of the total.




SCHEDULE, Drug development 7.5 ECTS


Premises
:





Lectures:


All lectures on the Chalmers campus:


EF
, Hörsals
vägen 1
1. This entrance is found

not
at Hörsalsvägen itself,
but at

the inner yard. Immediately inside you find elevator “C”. Take it
up to the 6
th

floor. As you exit the elevator and go into the hallway, take
a right to find EF.


VK
, Sven Hultins gata 6. Go thro
ugh the main entrance at Architecture,
and follow the signs

on the inside
.



Demonstrations:


a) HTS facility



b) transgene facility


In both cases at AstraZeneca Mölndal. Meet in the main lobby,
Pepparedsleden 1, Mölndal.




Day

Times

Room

Lecture/demon
stration

W 10
/11

8.00


㤮㐵

EF

Introduction to the course

Genetic model organisms: Yeast

(Per Sunnerhagen, CMB, GU)

Th 11
/11

8.00


㤮㐵



m牯瑥楮i a猠 a 瑡tge琠 浯mec畬攺u 牡瑩潮o氠
摲畧⁤ 獩s渠

⡇ö渠䭡牬獳潮Ⱐ乍r⁣e湴敲Ⱐ䝕)


㄰⸰〠



⸴.



佶l牶楥眠
潦o 瑨攠 浯摥m渠 灲潣e獳s 潦o
摲畧⁤ 癥汯灭e湴

⡂櫶牮⁌ö湡摬敲Ⱐ䅳瑲Iwe湥ca)

c‱
⼱/

ㄳ⸱㔠


ㄵ⸰1



䝬潢d氠數灲p獳s潮⁡湡汹獩s㨠數灲p獳s潮Ⱐo

浯摩晩fa瑩潮o栠楮he牡c瑩潮

⡁湤n牳⁂汯l扥牧ⰠI䵂Ⱐ䝕)

t‱
⼱/


〰0


㤮㐵



䝥湥瑩c潤敬 ga湩獭猺s
C. elegan
s

(Marc Pilon, CMB, GU)

Th 18/11

8.00


㤮㐵

EF

Transgenic mice as disease models

(Margit Mahlapuu, Dept. Medicine,
GU)


10.00



⸴.

VK

Protein as a target molecule: NMR and
screening in drug discovery

(Martin Billeter, Biochemistry, GU)

F 19
/11

13.15



ㄵ⸰1



f湦nc瑩潵猠摩獥a獥⁤牵 ⁤楳捯癥特




䅳瑲Awe湥ca⁰ 牳灥c瑩癥

(Tomas Lundqvist, AstraZeneca)

Th 25/11

10.00


ㄱ⸴1



pc牥e湩湧潤敬猠 渠摲ng⁤楳捯癥特

⡆a湹椠i楡湧Ⱐ䅳瑲Iwe湥ca)

c′
⼱/

ㄳ⸱㔠


ㄵ⸰1



c牡g浥湴
-
扡獥搠汥d搠de湥牡瑩潮

⡔桯
浡猠m汳l潮Ⱐ䅳瑲owe湥ca)

W 1
/12

8.00


9.45

EF

Chemical biology: the biologist’s
perspective

(Per Sunnerhagen, CMB, GU)

Th 2
/12

8.15


10

AstraZeneca

Demonstration transgenic facility

(Anne Edenro, AstraZeneca)


10.00


11.45


AstraZeneca

Demonstration

Automated screen and

Combinatorial chemistry

(Thomas Olsson / Peter Greasley,

AstraZeneca)

F 3
/12

13.15


15.00

EF

Design of pharmaceuticals directed

against proteins with known activity

(Morten Gr
øtli, Medicinal chemistry,
GU)

Th 9
/12

8.00


9.45

EF

Ap
plication of cancer drugs in the clinic

(Ola Hammarsten, Sahlgrenska)


10.00


11.45

VK

Modern drugs against cancer

(Fredrik Enlund, Sahlgrenska
)

F 10
/12

13.15


15.00

EF

Superantigen as a

candidate

therapeutic

agent
(Karin Lindkvist, CMB)

Questions bef
ore the exam

(Per Sunnerhagen)

Tue 14/12

8.30


12.30

V

Written exam

S 18/12



Submission individual projects (E
-
mail)